Caris Life Sciences (CAI) Income from Continuing Operations (2024 - 2026)
Caris Life Sciences (CAI) recorded quarterly Income from Continuing Operations of 510000.0 in Q1 2026, down 100.62% quarter-over-quarter from 81957000.0 in Q4 2025, and up 99.5% on a YoY basis from 255635.47 in Q1 2025.
Caris Life Sciences (CAI) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Caris Life Sciences' Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 510000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 99.5% year-over-year to 510000.0; the TTM figure through Mar 2026 stood at 33982000.0 (up 112.43% YoY), while the FY2025 annual figure was 68088000.0, up 75.85% from the prior year.
- Income from Continuing Operations was 510000.0 for Q1 2026 at Caris Life Sciences, down from 81957000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 81957000.0 in Q4 2025 to a low of 102581000.0 in Q1 2025.
- Historically, Income from Continuing Operations has averaged 29932625.0 across 3 years, with a median of 51566500.0 in 2024.
- Biggest YoY gain for Income from Continuing Operations was 321.82% in 2025; the steepest drop was 8.47% in 2025.
- A 3-year view of Income from Continuing Operations shows it stood at 36947000.0 in 2024, then soared by 321.82% to 81957000.0 in 2025, then sank by 100.62% to 510000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 510000.0 (Q1 2026), 81957000.0 (Q4 2025), and 24325000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Caris Life Sciences | 5.22 Bn | 4.40 Bn | 171.13 Mn | -510,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -510,000.00 |
| Dec 31, 2025 | 81.96 Mn |
| Sep 30, 2025 | 24.33 Mn |
| Jun 30, 2025 | -71.79 Mn |
| Mar 31, 2025 | -102.58 Mn |
| Dec 31, 2024 | -36.95 Mn |
| Sep 30, 2024 | -67.73 Mn |
| Jun 30, 2024 | -66.19 Mn |